« Previous Next » American Journal of Cardiology
Volume 91, Issue 6 , Pages 742-743 , 15 March 2003

Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition

Leslie Cho, MD
- Department of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA
- Dr. Cho’s address is: Department of Cardiovascular Medicine, Loyola University Medical Center, 2160 S. First Ave Bldg 110 Room 6215, Maywood, Illinois 60153, USA.
Derek P. Chew, MBBS
- Department of Cardiology, University of Adelaide, Adelaide, Australia
David J. Moliterno, MD
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Marco Roffi, MD
- Department of Cardiology, University of Zurich, Zurich, Switzerland
Stephen G. Ellis, MD
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Irving Franco, MD
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Christopher Bajzer, MD
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Deepak L. Bhatt, MD
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Khosrow Dorosti, MD
- Department of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA
- Department of Cardiology, University of Adelaide, Adelaide, Australia
- Department of Cardiology, University of Zurich, Zurich, Switzerland
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Conrad Simpfendorder, MD
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Murat Tuzcu, MD
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Jay S. Yadav, MD
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Sorin Brener, MD
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Russell Raymond, MD
- Department of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA
- Department of Cardiology, University of Adelaide, Adelaide, Australia
- Department of Cardiology, University of Zurich, Zurich, Switzerland
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Patrick Whitlow, MD
- Department of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA
- Department of Cardiology, University of Adelaide, Adelaide, Australia
- Department of Cardiology, University of Zurich, Zurich, Switzerland
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Eric J. Topol, MD
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
A.Michael Lincoff, MD
- Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

Received 14 August 2002 ,Revised 14 November 2002 ,Accepted 14 November 2002.

References

Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 1994;90:1522–1536
- MEDLINE
Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764–769
- MEDLINE
- CrossRef
Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina (final report reanalysis of the Bivalirudin Angioplasty Study). Am Heart J. 2001;142:952–960
Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization (results of the Comparison of Abciximab Complications with Hirulog for ischemic Events Trial (CACHET)). Am Heart J. 2002;143:847–853